{"entity":{"id":"biased-agonism","kind":"term","name":"Biased agonism and pathway-dependent receptor response","aka":["ligand bias","agonist bias","biased agonism","functional selectivity at receptors"],"tldr":"Two ligands at the same receptor can favor measured response pathways differently. That comparison depends on the reference ligand, assays and cellular system.","summary":"Biased agonism compares the relative signaling behavior of ligands across specified outputs at the same receptor. Binding, intrinsic receptor activation, pathway amplification and baseline activity can contribute differently to observed curves. A potency difference between two assays does not by itself isolate ligand-specific bias. Preserve the reference ligand, endpoints, receptor expression, timing and model assumptions used to estimate it.","asOf":"2026-11-08","links":[{"label":"Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.","url":"https://pubmed.ncbi.nlm.nih.gov/24434717/"},{"label":"Estimation of the receptor-state affinity constants of ligands in functional studies using wild type and constitutively active mutant receptors: Implications for estimation of agonist bias.","url":"https://pubmed.ncbi.nlm.nih.gov/27725245/"},{"label":"A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data.","url":"https://pubmed.ncbi.nlm.nih.gov/31244653/"}],"tags":[],"related":["receptor-reserve","binding-affinity-and-kinetics","agonist-antagonist","signalling-pathway"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ehlert and colleagues’ methods analyzed receptor-state affinities and pathway sensitivity using analytical proofs, simulations and previously published data. The constitutively active-mutant approach assumes that the mutation changes receptor-state equilibrium without changing ligand affinities and requires checking that assumption. These method studies do not establish clinical superiority of a biased ligand or validate every cellular assay."],"category":"Clinic basics"},"route":"/terms/biased-agonism/","neighbours":{"term":[{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/"},{"id":"binding-affinity-and-kinetics","kind":"term","name":"Binding affinity, occupancy and enzyme kinetics","route":"/terms/binding-affinity-and-kinetics/"},{"id":"receptor-reserve","kind":"term","name":"Receptor reserve and system-dependent response","route":"/terms/receptor-reserve/"},{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/"}]}}